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It is well known that the peripheral peptide YY (PYY)-central
neuropeptide Y (NPY) Y2 receptor axis plays an important
role in promoting negative energy balance regulation. Both
the hypothalamus andmedulla oblongata express a high level
of Y2 receptors; however, the functional role of this receptor
in chronic high-fat diet-induced obesity has not been fully
examined. Using quantitative autoradiography, this study
measuredbindingdensities of total [125I]PYYandY2receptors
in the hypothalamus and medulla of chronic high-fat diet-
induced obese (DIO), obese-resistant, and low-fat-fed mice.
Plasma PYY was also measured using RIA after 22 wk of di-
etary intervention. The results revealed that bodyweight gain
was significantly higher in the obesemice, comparedwith the
lean mice. Furthermore, PYY and NPY Y2 receptor binding
densities in the medulla of the obese mice were significantly
higher, compared with the lean mice, whereas the level of
plasma PYY was significantly lower in the DIO mice than the
low-fat-fed mice. In conclusion, this study showed that the
DIO mice had low plasma PYY, which may have caused a
compensatory up-regulation of PYY and Y2 receptor densities
in the medulla. A low-level response of PYY-medullary regu-
lation to positive energy balance may have contributed to the
development of high-fat diet-induced obesity in DIO mice;
conversely, a normal response of this regulatory axis in the
obese-resistant mice may have contributed to the mainte-
nance of body weight while on a high-fat diet. (Endocrinology
148: 4704–4710, 2007)
PEPTIDE YY (PYY) is a member of the pancreaticpolypeptide family, which is structurally and function-
ally related to the neuropeptide Y (NPY) family (1, 2). PYY
is mainly secreted from the endocrine L cells of the small and
large intestine and released into the circulation in response
to ingestion of food, especially in the presence of a fatty meal
(3, 4). At present, it is known that the peripheral adminis-
tration of PYY acutely inhibits food intake (5, 6). PYY has a
high affinity to NPY Y2 receptors that is subsequently fol-
lowed by NPY Y1 and Y5 receptors (7). Furthermore, it has
been suggested that PYY works via the NPY Y2 receptor to
suppress the amount of food intake (8).
In the hypothalamus, many studies have found that PYY
acts on NPY Y2 receptors in the arcuate nucleus to decrease
food intake (9–12). Additionally, it is known that themedulla
has a high level of binding to PYY (13, 14). However, cur-
rently no information is available in regard to hypothalamic
and medullary PYY and Y2 receptor regulation in diet-in-
duced obesity. Using a chronic high-energy diet-induced
obese (DIO) and diet-resistant (DR) mouse model, this study
aimed to examine the levels of plasma PYY together with
PYY and Y2 receptor binding density in the hypothalamus
and medulla oblongata. It is hypothesized that differential
regulation exists in the peripheral PYY and its hypothalamic
and medullar binding densities between the mice prone or
resistant to diet-induced obesity.
Materials and Methods
Animal model and diets
Forty-eight C57BL/6 mice aged 9 wk were obtained from the Animal
Resource Centre (Perth, Western Australia) and kept in a temperature-
controlled room at 22 C with a 12-h light, 12-h dark cycle. For the first
week, all micewere given lab chow ad libitum to acclimatize them to their
new surroundings. The mice were then placed in separate cages. Thirty-
sixmicewere randomly chosen and fed a high-fat diet (Table 1) ad libitum
and retrospectively assigned into one of three groups: DIO (n 12), DR
(n  12), and intermediate, based on their body weight after 22 wk on
this diet (15, 16). The other 12 mice were used as the control group (LF)
and were given ad libitum low-fat diet (Table 1) for 22 wk. During the
experiment, 24-h food intake and body weight were measured weekly.
All experimental procedures were approved by the Animal Ethics Com-
mittee, University of Wollongong, Australia, and complied with the
Australian Code of Practice for the Care and Use of Animal for Scientific
Purposes.
Tissue preparation and body composition analysis
After 22 wk of feeding on the high- or low-fat diets, mice were given
an overdose injection of sodium pentobarbitone (120 mg/kg, ip). All
mice were killed between 0700 and 0900 h to minimize circadian vari-
ation. Blood samples were collected from the right ventricle of the heart.
Brains were immediately removed after death and frozen in liquid
nitrogen. Coronal brain sections (14 m) were cut at 17 C using a
cryostat and thaw-mounted onto polysine microscope slides (Menzel
GmbH & Co. KG, Braunschweig, Germany).
Total body fat mass was measured via lipid extraction technique (17).
Briefly, the mouse carcass was dried using a freeze drier (FD3 Freeze
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drier; Dynavac Engineering, Sydney, Australia) andweighed before and
after the drying process. After that the body was cut into smaller por-
tions then placed into cellulose thimbles. They were placed in a Soxhlet
apparatus containing petroleum ether, which resulted in complete ex-
traction of all neutral lipids. The total body fat mass was calculated by
measuring the difference in body weight before and after the extraction.
[125I]PYY binding autoradiography
PYY binding densities were visualized using [125I]PYY as previously
described (18). Sections were preincubated for 30min in Krebs Henseleit
Tris (KHT) buffer [118 mm NaCl, 4.8 mm KCl, 1.3 mm MgSO4, 1.2 mm
CaCl2, 50mm glucose, 15mmNaHCO3, 1.2mmKH2PO4, 10mm Tris (pH
7.3)]. Slides were then incubated for 120 min in KHT buffer containing
0.1% BSA, 0.05% bacitracin, and 25 pm [125I]PYY (Sigma Aldrich, St.
Louis, MO). Nonspecific binding was determined by incubating in the
same incubation buffer plus 1 m porcine NPY (Sigma Aldrich). Slides
were then washed (3  5 min) in ice-cold buffer, dipped in ice-cold
distilled water and dried under a gentle stream of cool air. Slides were
stored overnight in desiccators and then apposed to X-OMAT AR film
(Kodak, Rochester, NY) in the presence of standardmicroscales for 12 d.
Autoradiographs were developed using Kodak D-19 developer and
fixedwith IlfordHyphamRapid Fixer (Ilford Imaging, Clayton, Victoria,
Australia).
Y2 receptor binding autoradiography
To measure the Y2 receptor binding density, [Leu31, Pro34]NPY (por-
cine; SigmaAldrich) was included in the incubating solution tomask the
NPY Y1 and Y5 receptors (19). Briefly, sections were preincubated for 30
min inKHTbuffer. Slideswere then incubated for 120min inKHTbuffer
containing 0.1% BSA, 0.05% bacitracin, 100 nm [Leu31, Pro34]NPY, and
25 pm [125I]PYY (Sigma Aldrich). Porcine NPY (1 m) was used to
determine nonspecific binding as mentioned above. The remaining
methods were the same as for [125I]PYY binding autoradiography.
Quantification
Autoradiography images were captured and analyzed using a com-
puter-assisted image analysis system, Multi-Analysis, connected to a
GS-690 imaging densitometer (Bio-Rad Laboratories, Hercules, CA), as
the detailed description was given previously (20). The density of bind-
ingwas calculatedwith the aid of the standard curve generated from the
microscales, which then converted to nanocuries per milligram of tissue
equivalent. Individual medullary nuclei were identified with reference
to a standard mouse brain atlas (21).
Plasma PYY
A commercially available PYY (rat, mouse, porcine) RIA kit (Phoenix
Pharmaceuticals, Belmont, CA) was used to measure the plasma level of
PYY. The kit had 100% cross-reactivity with both circulating forms of
PYY, PYY1–36, and PYY3–36 (22, 23).
Statistical analysis
Data were presented as means  sd. We used the SPSS statistical
package 13.0 (SPSS Inc., Chicago, IL) for our statistical analyses. A
two-way repeated ANOVA (treatment  weeks as repeated measures)
was used to analyze data of the weekly body weight and energy intake.
Data of PYY binding density, Y2 receptor binding density, and plasma
PYY measurements were assessed by one-way ANOVA, followed by a
post hoc Tukey-Kramer honestly significant difference test for multiple
comparisons among the groups. To analyze correlations between vari-
ables measured, a Pearson test was performed.
Results
Body weight, fat mass, and energy intake
A two-way repeated ANOVA revealed significant main
effects of both treatment (F2,33  70.19, P  0.001) and the
repeated measurement weeks (F11,363 387.82, P 0.001) on
weight gains. There was also a significant interaction be-
tween the two factors (F22,363  47.13, P  0.001). Although
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FIG. 1. Body weight (A), weekly energy intake (B), and average en-
ergy intake (C) of chronic DIO, DR, and the control (LF)mice through-
out 22 wk of feeding on the high- or low-fat diet. Data are represented
as mean SD. Error bars are omitted when smaller than the symbol.
*, P  0.05 DIO vs. LF; #, P  0.05 DIO vs. DR.
TABLE 1. The food composition of the diet used in the
experiment
LF diet HF diet
Cornstarch, kcal, % 67.73 38.83
Sucrose, kcal, % 6.51 5.39
Copha, kcal, % 15.75
Beef tallow, kcal, % 15.75
Sunflower oil, kcal, % 9.75 8.07
Gelatine, kcal, % 5.56 4.6
Casein, kcal, % 10.45 11.6
Fiber, g/kg 51 51
Minerals, g/kg 67 67
Vitamins, g/kg 13 13
HF, High fat; LF, low fat.
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there was a consistent increase in the body weight in all
groups, the DIO mice had significantly higher body weight
gain than theDR (P 0.007) andLF (P 0.001)mice through-
out the treatment period (Fig. 1A). The final bodyweight gain
of the DIO groupwas 123 and 190%higher (42.7 0.8 g) than
the DR (31.6 0.5 g) and LF mice, respectively (30.0 0.8 g;
F2,33  86.54, P  0.001; DIO vs. DR, P  0.001; DIO vs. LF,
P 0.001). Furthermore, the total fat mass of the DIO group
was 129 and 192% heavier (13.3  0.6 g) than the DR (6.5 
0.3 g) and LF mice, respectively (5.4 0.4 g; F2,33 94.4, P
0.001; DIO vs. DR, P  0.001; DIO vs. LF, P  0.001).
A two-way repeated ANOVA also revealed significant
effects of treatment (F2,33 19.95, P 0.001) and the repeated
measurement weeks (F10,330  15.49, P  0.001) on food
intake along with a significant interaction between the two
factors (F20,30  7.94, P  0.001). Throughout the treatment
period, the DIO mice had a significantly higher energy in-
take, compared with DR mice (P  0.001; Fig. 1B). Although
there was a fluctuation in the energy intake of the LF mice
on the various measurement days, overall, the DIOmice had
a higher energy intake than the LF mice (P  0.001; Fig. 1B).
No significant differences were found between the DR and
LFmice. Furthermore, the average energy intake throughout
the 22 wk of feeding was significantly higher in the DIO
group (60.49  0.87 kJ per 24 h), compared with the DR
(53.03  0.91 kJ per 24 h) and LF groups (55.13  0.71 kJ per
24 h; F2,33  21.31, P  0.001; DIO vs. DR, P  0.001; DIO vs.
LF, P  0.001; Fig. 1C).
Plasma PYY
The level of plasmaPYYwas significantly lower in theDIO
group (32%), compared with the LF group (F2,21  6.26, P 
0.01; DIO vs. LF, P  0.007; Fig. 2). No significant difference
was found in the levels of plasma PYY between the DR and
LF groups.
PYY binding density and Y2 receptor binding density in the
hypothalamus of DIO, DR, and LF mice
Although there was a trend that the obese mice had a
higher PYY binding density, compared with the lean mice,
in the dorsomedial and ventromedial hypothalamus, these
differences were not significant (Table 2). There was not any
significant difference in PYY binding density in the arcuate
nucleus and lateral hypothalamus. Furthermore, there were
no significant differences of Y2 receptor binding density in
any hypothalamic nuclei (Table 2) between the groups.
PYY binding density in the medulla of DIO, DR, and
LF mice
A one-way ANOVA revealed that there were significant
differences between the groups for PYY binding density in the
dorsal vagal complex (DVC) containing the nucleus of solitary
tract and dorsalmotor nucleus of vagus nerve (F2,10 6.76, P
0.019), intermediate reticular zone (IRt; F2,10 17.34,P 0.001),
and ventrolateral medulla (VLM; F2,10  7.60, P  0.014) area
(Figs. 3 and 4). In the DVC, the DIO mice had higher PYY
binding density than that of the DR (68%, P  0.015) and LF
mice (37%, P  0.079). Similar differences were also observed
in the intermediate reticular zone, in which the DIO had a
significantly higher binding density, compared with the DR
(171%, P  0.001) and the LF group (96%; P  0.004). In the
VLM, the DIO mice also had a significantly higher binding
density than the DR (122%, P 0.022) and the LF group (134%,
P  0.015).
Y2 receptor density in the medulla oblongata of DIO, DR,
and LF mice
TheDIOmice had significantly higher Y2 receptor binding
density (Figs. 3 and 4), in the DVC, compared with the LF
group (63%; F2,10  4.75, P  0.044; DIO vs. LF, P  0.041).
In the IRt, the DIO group had 47% higher binding density,
compared with the DR group (F2,10  6.92, P  0.02; DIO vs.
DR, P  0.023). In the VLM, there were no differences in the
binding density among the DIO, DR, and LF groups.
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FIG. 2. The plasma level of PYY in chronic DIO, DR, and the control
group (LF). Data are represented as mean  SD. *, P  0.01 vs. LF.
TABLE 2. The 125IPYY binding and Y2 receptor binding densities in various areas of the hypothalamus of chronic DIO, DR, and the
control (LF) mice
Brain area DIOa DRa LFa F(2, 10) P value
Total binding with 125IPYY
Arc 284.8  0.7 198.6  66.5 195.7  38.5 3.00 0.160
DMH 213.1  27.7 123.7  44.7 172.0  20.9 4.39 0.079
LH 224.6  30.1 131.2  46.1 177.9  42.7 3.02 0.138
VMH 248.60  49.3 138.6  41.4 168.3  27.9 5.02 0.064
Y2 receptor binding density
Arc 228.5  17.2 154.3  70.2 170.9  35.5 1.36 0.337
DMH 206.2  16.2 125.1  58.9 154.3  37.4 1.98 0.232
LH 222.1  5.3 131.2  51.0 162.6  42.4 2.83 0.151
VMH 189.5  30.9 139.9  38.2 143.4  23.7 1.72 0.269
Binding densities were quantified at the level of bregma 1.22, 1.70, and 2.18 mm. Arc, Arcuate nucleus; DMH, dorsomedial hypo-
thalamus; LH, lateral hypothalamus.
a Mean  SD.
4706 Endocrinology, October 2007, 148(10):4704–4710 Rahardjo et al. • PYY and Y2 Medullary Binding in Obese Mice
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 15 December 2014. at 21:46 For personal use only. No other uses without permission. . All rights reserved.
Correlation
A correlation analysis was carried out among the final
body weight, body fat mass, energy intake of the last week
of the dietary intervention, and the plasma PYY aswell as the
medullary PYY binding density and Y2 receptor binding
density of the DIO, DR, and LF mice (Table 3). Final body
weight was highly correlated to the plasma PYY and the PYY
binding densities in all measured areas as well as the Y2
receptor binding densities in the IRt and VLM. Total body fat
was also highly correlated to the plasma PYY, the PYY bind-
ing densities in all measured areas, and the Y2 receptor
binding density in the IRt and the VLM. The energy intake
of the last week was significantly correlated to plasma PYY
concentrations and the PYY binding densities and Y2 recep-
tor binding densities in the IRt and the VLM.
Discussion
The results of this study revealed a significant increase of
medullary PYY and Y2 receptor binding densities in the DIO
mice, compared with the DR and LF mice. This increased
binding density was accompanied by a decrease in plasma
PYY level.
It is known that PYY acts on NPY Y2 receptors in the
hypothalamic arcuate nucleus to decrease food intake (9–
12). Furthermore, Y2 receptor conditional knockout mice
have been shown to have a significant increase of food
intake (24). Although there is an abundant amount of NPY
receptor in the medulla (25, 26), to our present knowledge,
no information is available in respect to whether the med-
ullary NPY receptors are involved in the regulation of
body weight in high-fat diet-induced obesity.
This study found that the PYY and Y2 receptor binding
0
100
200
300
400
DIO DR LF
0
100
200
300
400
DIO DR LF
B
in
di
ng
 d
en
si
ty
 (n
C
i/g
 ti
ss
ue
)
DVC
 IRt
VLM
PYY binding Y2 receptor binding
 DVC
 IRt
VLM
#
#
#
#
*
*
*
0
100
200
300
400
DIO DR LF
0
100
200
300
DIO DR LF
0
100
200
300
400
DIO DR LF
0
100
200
300
DIO DR LF
B
in
di
ng
 d
en
si
ty
 (n
C
i/g
 ti
ss
ue
)
A
B
C
D
E
F
FIG. 3. The binding densities to
[125I]PYY (A–C) and Y2 receptor (D–F)
in the DVC, IRt, and VLM of chronic
DIO, DR, and the control (LF) mice.
Binding densities were quantified at
the level of bregma7.32. Data are rep-
resented asmean SD. *, P 0.05, DIO
vs. LF; #, P  0.05 DIO vs. DR.
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densities in the obese mice were significantly higher than
the lean DR and LF mice in most areas of the medulla
regulating autonomic function (DVC, IRt, and VLM). This
study also found that there was a positive correlation
between PYY binding density in these areas and final body
weight, energy intake, and body fat mass. Furthermore,
although a similar trend was found in some of the hypo-
thalamic nuclei (the dorsomedial and ventromedial hy-
pothalamus), the differences between the obese and lean
mice were not as significant as the findings in the med-
ullary areas. These findings have demonstrated that PYY
possibly acts to regulate energy balance via the medulla to
control food intake rather than working exclusively in the
arcuate hypothalamic nucleus.
The differences in the binding density in the VLM im-
plied that there might be a difference between the obese
and lean mice in their baroreceptor regulation by PYY (27).
This is supported by the finding that the VLM is a site that
plays a crucial role in baroreceptor regulation in hyper-
tensive obese rats (28). In general, there is a tendency for
obese subjects to have higher blood pressure (29–31).
However, to our present knowledge, there is no literature
available that evaluates the baroreceptor regulation in a
diet-induced obese mouse model.
Studies have shown that an injection of PYY into the
DVC causes similar neuronal inhibition as an injection of
a Y2 agonist (13). This implies that PYY binds to Y2 re-
ceptors in the medulla to cause these effects. In the present
study, the obese mice were found to have a significantly
higher Y2 receptor binding density in the DVC and IRt
areas of the medulla, compared with the lean mice. Be-
cause the magnitude of the significance in the correlation
between Y2 receptor binding density and body weight,
food intake, and body fat mass was less than that of PYY
binding density, it is possible that the mechanism in which
the PYY regulates the food intake in the medulla might be
not only acting solely on the NPY Y2 receptor binding
density as previously thought but may also by acting
through the NPY Y1 and Y5 receptors.
Plasma PYY in the obese mice in this study was found
to be lower than the high-fat-fed lean and the low-fat-fed
lean mice. Other studies in humans and rodents have also
described a reduced amount of plasma PYY in obese pop-
ulations (32, 33). This attenuated response of PYY release
in obese populations (34) has been shown to cause an
insufficient inhibitory effect on feeding (35, 36). Findings
from the analysis of PYY null mice also confirm that a
depleted amount of PYY can cause an increase in food
intake (37). This study is the first to analyze the peripheral
plasma PYY as well as its receptor binding density in a
dietary-induced obese animal model. Based on our results,
we suggest that the up-regulation of the medullary PYY
binding density in the DIOmice may be a response to their
low level of plasma PYY. However, it is obvious that in the
diet-induced obese mice, this compensatory regulation of
PYY was not effective enough to reduce the food intake in
this group. This is possibly due to the low amount of PYY
bound as a result of the low plasma PYY the obese mice
had. It is important to note that PYY-immunoreactive neu-
rons have been found in the medulla (38, 39). Therefore,
TABLE 3. The correlation among the body weight, food intake, and plasma level of PYY and binding densities of 125IPYY and Y2
receptor in the medulla nuclei
After 22 wk of high-fat diet
Final body weight Total body fat Energy intake in last week
R value P value R value P value R value P value
Plasma PYY 0.468 0.021 0.475 0.019 0.462 0.023
Total binding with 125IPYY
DVC 0.738 0.010 0.738 0.010 0.516 0.104
IRt 0.842 0.001 0.838 0.001 0.671 0.024
VLM 0.803 0.003 0.817 0.002 0.777 0.005
Y2 receptor binding density
DVC 0.495 0.122 0.468 0.146 0.431 0.186
IRt 0.727 0.011 0.747 0.008 0.767 0.006
VLM 0.618 0.043 0.634 0.036 0.841 0.001
FIG. 4. Photographs depicting the [125I]PYY bindings (B–D) and Y2
receptor bindings (B’ to D’) in the medulla of chronic DIO (B and B’),
DR (C and C’), and the LF (control) group (D and D’). The line box (A)
indicates where the section was taken.
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a local effect of PYY neurons on PYY binding and Y2
receptor binding cannot be excluded. Further studies are
needed to confirm this issue by measuring the levels of
PYY mRNA and protein expression in the medulla of DIO
mice.
Furthermore, the results of this study suggested that the
elevation of the level of plasma PYY might be effective at
decreasing food intake. However, previous studies have
shown that there were different effects of the peripheral
and central administration of PYY on food intake (40, 41).
Peripheral injections of PYY caused significantly lower
food intake in humans and rodents (including in a DIO
mouse model) (2, 6, 11). Nevertheless, an intracerebro-
ventricular injection of PYY induced higher food intake
(42, 43). On the contrary, when PYY was injected directly
into the hypothalamic arcuate nucleus, food intake was
significantly decreased (6), an effect that was similar to
that observed after a peripheral injection of PYY.
As for the difference in the effects of peripheral vs.
central injections of PYY, one possible explanation could
be that when PYY was injected peripherally, it was trans-
ported in the blood directly into areas in the brain with a
high binding affinity to PYY, such as the hypothalamic
arcuate nucleus (and possibly also the DVC), via the highly
permeable blood-brain barrier. In these areas, PYY may
have bound to the anorexigenic NPY Y2 receptor causing
a decrease in food intake, which has been evidenced in Y2
knockout mice in which the anorectic effect of peripheral
PYY injection was diminished (6). However, when injected
centrally into the ventricle, it was likely that PYY bound
to the more orexigenic NPY receptors, such as Y1 and Y5,
caused an increase in food intake. This was also supported
by the finding that the orexigenic effect of intracerebro-
ventricular PYY was reduced in Y1 and Y5 receptor knock-
out mice (43).
In conclusion, it is clear that in diet-induced obese mice,
there is a dysfunctional PYY regulation. Although there was
an up-regulation in PYY and Y2 receptor binding in the
medulla, the reduced amount of plasma PYY in the obese
mice may have contributed to their high energy intake and
subsequent weight gain.
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